Why the study?
Recombinant APOA5 produced at low yield in bacteria had low solubility under physiological buffer conditions, limiting structure-function studies.
Population
C57BL/6J mice orally gavaged with Intralipid
Comparison
Injected recombinant APOA5
Design
Preclinical laboratory and in vivo animal study
Authors
Loading...
May enable structure-function studies of APOA5; leaves open therapeutic translation in hypertriglyceridemia.
A novel high-yield bacterial expression system produces soluble, functional recombinant APOA5 that can inhibit postprandial triglyceride accumulation in vivo, enabling future structure-function studies.
Castleberry et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: